G

Generation Bio Co
D

GBIO

1.42500
USD
-0.04
(-2.40%)
Market Closed
Volume
3,421
EPS
-2
Div Yield
-
P/E
-1
Market Cap
95,179,771
Related Instruments
    ABT
    ABT
    0.850
    (0.74%)
    118.950 USD
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    IDXX
    IDXX
    -2.54
    (-0.60%)
    421.30 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    R
    RARE
    -2.865
    (-6.02%)
    44.745 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    521.81 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    464.69 USD
    More
News

Title: Generation Bio Co

Sector: Healthcare
Industry: Biotechnology
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.